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Abstract
Rationale and objectives Cognitive deficits, including an
impaired ability to shift perceptual attentional set, belong to
the core features of schizophrenia, are associated with
prefrontal cortical dysfunctions, and may involve glutamate
NMDA receptors. Although phencyclidine disturbs cogni-
tive flexibility, little is known about the effects of ketamine
and other NMDA antagonists that differ in receptor subunit
selectivity, particularly in the mouse species.
Methods At different times following the administration of
ketamine, the NMDA NR2B-subtype specific antagonist
Ro 25-6981, or the atypical antipsychotic sertindole, male
C57Bl/6J mice were investigated in a modified version of
attentional set-shifting task (ASST).
Results Specific extra-dimensional shift (EDS) deficit was
observed in all control mice. As revealed by the increased
number of trials, time and errors to reach criterion,
ketamine at 10 or 20 mg/kg given 50 min prior to sessions,
but not at 10 mg/kg given 3 or 24 h prior to sessions, further
worsened the EDS performance. Sertindole (2.5 mg/kg)
prevented ketamine-induced cognitive inflexibility, although
it did not affect ASST performance when given alone. In
contrast to ketamine, Ro 25-6981 at 10 but not 3 mg/kg,
reduced the number of trials and errors to criterion, suggesting
a facilitation of cognitive flexibility. Finally, as revealed by the
number of trials and time to criterion measures, Ro 25-6981
(10 mg/kg) administration to ketamine (10 mg/kg)-pretreated
mice inhibited ketamine-induced cognitive inflexibility.
Conclusion The present study provides an improved and
reliable mouse ASST protocol and confirms and extends
previous findings demonstrating that NR2B subunit-
selective antagonists improve cognitive processes.
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Introduction
Schizophrenia is characterized by well-known “positive”
and “negative” symptoms and by less recognized cognitive
deficits in executive functions, working memory, and
attention (Bowie and Harvey 2006). These cognitive
deficits are present at the onset of illness, persist without
remission throughout most of patients’ lives, and may
precede the development of “positive” symptoms (Brewer
et al. 2006). Flexibility in response to a change in
attentional set toward stimuli is controlled by the prefrontal
cortex (PFC) and is commonly assessed in patients using
the Wisconsin Card Sorting Test (WCST; Grant and Berg
1948; Elliott et al. 1998). A poor WCST performance is
observed not only in schizophrenics but also in patients
with frontal lobe damage (Pantelis et al. 1999).
The impairments in executive functions observed in
WCST in humans can be investigated using a rodent
version of the attentional set-shifting task (ASST) devel-
oped by Birrell and Brown (2000). The ASST requires
animals to initially learn a rule and form “an attentional set”
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within the same stimulus dimension, by discriminating
between, e.g., the odors associated with food reward.
During the extra-dimensional (ED) shift, the crucial and
most difficult part of the test, the subjects have to rapidly
switch their attention to a new and previously irrelevant
stimulus dimension and to discriminate between, e.g., the
media covering the food reward. Although an increasing
number of laboratories have successfully used the ASST in
rats, most of the attempts to adapt this procedure for use in
mice have failed to demonstrate an ED shift deficit
(Colacicco et al. 2002; Laurent and Podhorna 2004; Zhuo
et al. 2007; Levi et al. 2008). Only one procedure,
described by Garner et al. (2006) and replicated with slight
modification by Papaleo et al. (2008), has shown a
significant extra-dimensional shift (EDS) phase deficit in
this species. However, our laboratory was unable to
demonstrate an ED shift impairment even with these
modifications, and therefore, the first goal of the present
study was to establish the conditions allowing for the
measurement of reliable set-shifting in mice.
Converging lines of evidence indicate the involvement
of glutamate NMDA transmission in schizophrenia. A
single dose of an NMDA receptor antagonist, such as
phencyclidine (PCP) or ketamine, induces symptoms of
acute psychosis in healthy volunteers (Luby 1959; Javitt
and Zukin 1991). Because these symptoms are indistin-
guishable from some symptoms of schizophrenia (Krystal
et al. 1994), antagonists of NMDA receptors are routinely
used in preclinical research as a pharmacological model of
this psychosis (Olney and Farber 1995; Jentsch and Roth
1999). The acute administration of ketamine impairs
attentional set-shifting as measured by the WCST in healthy
humans (Krystal et al. 2000) and in the rat (Nikiforuk et al.
2010). Therefore, the second goal of the present study was
to investigate the ketamine-induced impairment of ASST in
mice.
Compared to conventional antipsychotics, relatively
novel atypical compounds, such as sertindole, display an
advantageous profile of pro-cognitive actions in schizo-
phrenia. A recent multi-center, randomized, double-blinded
clinical trial indicated a beneficial effect of sertindole on
executive functions in patients with schizophrenia
(Gallhofer et al. 2007); this medication also reduced the
debilitating effects of ketamine in the Stroop task in healthy
volunteers (Vollenweider et al. 1999). Several preclinical
studies have shown that sertindole reduces or reverses the
impairing effects of subchronic PCP treatment (Rodefer et
al. 2008; Broberg et al. 2009; Goetghebeur and Dias 2009)
and of an acute dose of ketamine (Nikiforuk et al. 2010) in
the rat ASST. An obligatory step in the validation of a
given procedure relies on the demonstration of a positive
effect of the medication previously found to be effective in
similar conditions. The third goal of the present study was
to investigate whether sertindole could reverse ketamine-
induced deficits in the mouse version of the ASST.
NMDA receptors are heteromers composed of an obliga-
tory NR1 (mouse zeta 1) subunit and of at least one type of the
NR2 (NR2A–NR2D; mouse epsilon 1–4) subunits (Laube et
al. 1998; Schorge and Colquhoun 2003). The type of NR2
subunit constituting the NMDA receptor affects its physio-
logical and pharmacological properties (Monaghan and
Larsen 1997; Loftis and Janowsky 2003). In addition, the
brain distribution of NR2 subunits is not uniform (Monyer et
al. 1994; Wenzel et al. 1995); although NR2A messenger
RNA (mRNA) is distributed particularly in the cerebral
cortex, hippocampus, and cerebellum, the NR2B transcript is
selectively present in the forebrain with a high level of
expression in the cerebral cortex, hippocampus, septum,
caudate–putamen, and olfactory bulb. The NR2C mRNA is
expressed predominantly in the cerebellum, and the NR2D
transcript is detected in the thalamus, brain stem, and
olfactory bulb. The NR2C and NR2D transcripts are found
in a subset of hippocampal neurons, which are most likely
interneurons (Ozawa et al. 1998).
This pattern of distribution suggests that subunit-specific
NMDA antagonists may have differential effects under various
physiological and pathological conditions (Skolnick et al.
2009). Although ketamine is regarded as an NR2-unspecific
antagonist (Dravid et al. 2007), recent data indicate that it
mainly affects NR1/2C and NR1/2D NMDA receptors
(Kotermanski and Johnson 2009). Due to its antagonistic
action at hippocampal NMDA receptors, ketamine may cause
cortical disinhibition, which is relevant to some symptoms of
schizophrenia, including cognitive inflexibility (Greene 2001;
Homayoun and Moghaddam 2007; Lisman et al. 2008). In
contrast, the NR2B-selective antagonist, CP-101,606 (trax-
oprodil), under certain test conditions, improves cognitive
flexibility as assessed by the five-choice serial reaction time
task (5-CSRT; Higgins et al. 2005). Therefore, the fourth goal
of the present study was to investigate the effects of an
NR2B-selective antagonist alone and in combination with
ketamine in the ASST procedure. We used the Ro 25-6981
compound [(aR,bS)-a-(4-hydroxyphenyl)-b-methyl-4-(phenyl-
methyl)-1-piperidinepropanol hydrochloride] that is character-
ized by a >5,000-fold selectivity for NR2C/NR2B over
NR2C/NR2A subunits of the NMDA receptor, use-
dependent binding properties and neuroprotective effects
against glutamate toxicity (Fischer et al. 1997).
Materials and methods
Ethics
The experiments were conducted in accordance with the
NIH Guide for the Care and Use of Laboratory Animals
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and were approved by the Ethics Committee for Animal
Experiments, Institute of Pharmacology.
Animals
The studies were performed on male C57Bl/6J mice
(Institute of Pharmacology breeding facility, originating
from the Jackson Laboratories and purchased from Charles-
River, Germany) weighing approximately 24 g and being
approximately 7 to 8 weeks old at the start of the
experiment. The mice were housed in standard laboratory
cages under standard colony A/C-controlled conditions:
room temperature of 21±2°C, humidity of 40% to 50%,
and a 12-h light/dark cycle (lights on at 06:00). The mice
were individually housed and mildly food deprived (2.9 g of
food pellets per day), with ad libitum access to water for
1 week prior to testing. Mice were food restricted throughout
the experiment to maintain approximately 85% of their
initially body weight. Behavioral testing was performed
during the light phase of the light/dark cycle. Different groups
of animals were used in different drug experiments.
Attentional set-shifting task procedure
The experiments were performed according to the proce-
dure for mice described by Garner et al. (2006) and Papaleo
et al. (2008) with some modifications. The mice were tested
in a black acrylic U-shaped maze apparatus (W×L, 39×
39 cm) with a wire grid floor. The starting compartment
provided an entrance via guillotine doors into two identical
testing compartments. A bowl with water was placed in the
starting compartment to allow mice free access to water
throughout the whole training procedure. The food reward
(1/8 of Honey Nut Cheerio, Nestle®) was presented in
containers (glass dishes, 5 cm in diameter, 3 cm in depth).
The containers were defined by a pair of cues with two
stimulus dimensions: different kinds of digging media and
distinct odors (2 μl of a flavoring essence, Dr. Oetker®,
Poland, on a piece of the blotting paper fixed to the external
wall of a glass dish prior to use). Different containers were
used for each combination of the digging medium and odor.
Stimulus dimensions are shown in Table 1.
The entire study consisted of several experiments. Each
experiment was performed on three consecutive days with
training sessions 1 and 2 on the 2nd and 3rd days (Table 2).
Habituation (day 1)
On the first day of testing, mice were habituated to the
apparatus, containers, and food reward for 5 min. The four
phases of shaping were then initiated; the first three phases
with two trials each and the fourth phase with three trials were
performed sequentially. During each trial, the mouse was
placed in the starting compartment, and the guillotine door
was raised to allow entry to the test compartment with the
containers filled with the food reward. During the first phase,
the food reward was placed at the bottom of an empty
container. For the next phase, the containers were filled with
0.5 cm of wood shavings, and the food reward was placed on
top of the filling. In the third phase, the reward was placed
under a thin layer of wood shavings. In the final phase, the
food reward was buried under 2 cm of wood shavings. Once
the mice retrieved the food reward, they were allowed to
consume it before being returned to the starting compartment.
Session 1 (2nd day) and session 2 (3rd day)
Each mouse was trained to discriminate between pairs of
containers that differed in odor and/or the media covering
the food reward. This training was performed during two
sessions, which consisted of several phases with several
trials. During each trial, the animal was placed in the
starting compartment, and the guillotine door was raised to
give the mouse access to two containers, only one of which
contained the food reward. The food reward was buried
under the surface of distinct digging media. The first three
trials of each session were “free”, meaning that even after
an incorrect choice, the door remained open, and the mouse
was allowed to investigate and collect the food reward from
the opposite container. On subsequent trials, the door was
closed upon the animal’s entry to the compartment. If the
mouse started to dig in the un-baited container (i.e., the
container without the food reward), an error was recorded,
the trial was terminated, and the mouse was returned to the
starting compartment. Each mouse had to reach a criterion
of eight correct discriminations out of ten consecutive trials
to complete each phase. The inter-trial interval was
approximately 5 s, and the interval between consecutive
phases in a given session was approximately 45 s.
We followed the protocol of Papaleo et al. (2008) by
inserting additional phases (IDS2 and IDSR2). However, in
Dimension Exemplar pairs
Odor Orange Lemon Spicy Cream
Arrack Almond Vanilla Rum
Medium Fine gravel Crumpled tissue Cardboard Bamboo sticks
Beads Aluminum balls Plastic Polystyrene
Table 1 Pairs of different stim-
uli used in the mouse version of
the ASST
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contrast to the protocols of Papaleo et al. (2008) and Garner
et al. (2006), we divided the whole ASST procedure into
two sessions. The reason for using a two-session procedure
was that the mice appeared satiated when we attempted to
complete all of the phases of testing in 1 day. Therefore,
session 1 consisted of a warm-up habituation trial (identical
to the last trial of the habituation session) and five phases:
(1) simple discrimination (SD), (2) compound discrimina-
tion (CD), (3) compound discrimination reversal (CDR), (4)
intra-dimensional shift (IDS), and (5) intra-dimensional
shift reversal (IDSR). The overall testing time for one
animal during this session was approximately 60 to 70 min.
Session 2 also consisted of a warm-up habituation trial and
four phases: (1) intra-dimensional shift 2 (IDS2), (2) intra-
dimensional shift reversal (IDSR2), (3) EDS, and (4) extra-
dimensional shift reversal (EDSR). The overall testing time
for one animal during this session was approximately 40 to
50 min.
Thus, the mice were exposed to a series of increasingly
difficult discriminations during which they discriminated
within a dimension (the media covering the food reward)
that was relevant from the SD phase until the EDS phase.
At the EDS phase, the mouse had to start discriminating
within a new stimulus dimension (odors), and the previ-
ously relevant dimension (media) became irrelevant. This
schedule was used for all of the subjects and was based on
preliminary results that demonstrated a tendency for better
performance when the sequence of dimension change was
from the media to odors (data not shown). An example of
the entire task is shown in Table 2.
Drugs
Ketamine (10% aqueous solution of 115.34 mg/ml, Biowet,
Poland) and Ro 25-6981 compound [(aR,bS)-a-(4-hydrox-
yphenyl)-b-methyl-4-(phenylmethyl)-1-piperidinepropanol
Table 2 Detailed illustration of the present ASST procedure
Phase Dimension Discrimination 1 Discrimination 2
Session 1
SD Media Fine gravel vs. beads
CD Media Orange Arrack Orange Arrack
Fine gravel Beads Beads Fine gravel
CDR Media Orange Arrack Orange Arrack
Fine gravel Beads Beads Fine gravel
IDS Media Lemon Almond Lemon Almond
Crumpled tissue Aluminum balls Aluminum balls Crumpled tissue
IDSR Media Lemon Almond Lemon Almond
Crumpled tissue Aluminum balls Aluminum balls Crumpled tissue
Session 2
IDS2 Media Spicy Vanilla Spicy Vanilla
Cardboard Plastic Plastic Cardboard
IDSR2 Media Spicy Vanilla Spicy Vanilla
Cardboard Plastic Plastic Cardboard
EDS Odors Cream Rum Cream Rum
Bamboo sticks Polystyrene Polystyrene Bamboo sticks
EDSR Odors Cream Rum Cream Rum
Bamboo sticks Polystyrene Polystyrene Bamboo sticks
For each trial, mice were presented with either discrimination 1 or 2. In this example at the SD phase, all digging dishes had no odor, and the
subjects had to choose the beads as the correct digging medium (in italics). Note that the stimuli are the same for CD and CDR, for IDS and IDR,
and for EDS and EDSR
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hydrochloride] (Sequoia, UK) were dissolved in distilled
water. Sertindole (Sigma-Aldrich, Germany) was dissolved
in a minimum amount of 0.1 M hydrochloric acid and
diluted with water. Drugs were administered before each of
the two sessions. Therefore, the same animal received drug
treatment twice: ketamine at 50 min, 3 h or 24 h (IP), the
Ro 25-6981 compound at 30 min (IP), and sertindole at
120 min (PO). The ketamine “24-h” animals received the
drug approximately 1 h after the last trial of habituation and
approximately 1 h after session 1. All of the compounds
were administered in a volume of 10 ml/kg, and the doses
were chosen based on in-house data and published literature
(Higgins et al. 2005; Rodefer et al. 2008).
Statistics
The following parameters were measured for each mouse:
the number of trials to criterion, the number of errors to
criterion, and the time to reach criterion, which was defined
as eight correct choices out of ten consecutive trials.
Statistical analyses were performed with Statistica 8.0 for
Windows. The data from sessions 1 and 2 were calculated
separately using repeated measures ANOVAs. Whenever
significant interactions between the treatment conditions
and the phase of a session were found, the data were
analyzed with Newman–Keuls post hoc test; P<0.05 was
deemed significant.
Results
Modification of the ASST procedure: general remarks
The modification of the protocols of Garner et al. (2006)
and Papaleo et al. (2008) produced reliable set-shifting in
mice because in all replications, the subjects required
significantly more trials to reach the criterion during the
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Fig. 1 a–c Relationship be-
tween the time of ketamine
administration and attentional
set-shifting performance in
mice. Ketamine (10 mg/kg) was
administered 50 min and 3 or
24 h before both sessions. N=
8 mice per treatment condition.
Data are presented as the mean
± SEM. Symbols: *P<0.05 vs.
vehicle, iP<0.05 vs. IDS2
phase, kP<0.05 vs. ketamine
10 mg/kg group at 50 min (the
standard ketamine treatment);
Newman–Keuls post hoc test
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interaction factor between treatment conditions and the
session phase for all of the experiments’ session 1
measures, including trials, errors, and time to criterion,
yielded insignificant results.
Time-related effects of ketamine on ASST performance
As assessed by the interaction factors between treatment
condition and the phase of a given session, ketamine
(10 mg/kg, 3 or 24 h before the test) changed neither the
number of trials and errors nor the time to reach the
criterion at any of the discrimination phases (Fig. 1a–c). In
contrast, when administered 50 min before testing, ket-
amine significantly increased the number of trials (F(9, 84)=
2.72, P<0.01; Fig. 1a) and errors (F(9, 84)=2.86, P<0.01;
Fig. 1c) to criterion during the EDS phase. Although the time
to criterion in this group was increased (Fig. 1b), the
interaction (treatment × phase) for session 2 yielded
insignificant results.
Dose-related effects of ketamine on ASST performance
Ketamine (10 and 20 mg/kg, administered 50 min before the
test) dose-dependently, significantly, and specifically increased
the number of trials (F(6, 66)=17.49, P<0.001; Fig. 2a),
errors (F(6, 66)=8.22, P<0.001; Fig. 2b), and the time to
criterion (F(6, 66)=9.04, P<0.001; Fig. 2c) during the EDS
phase. In all three measures, the effects of 20 mg/kg ketamine
were significantly stronger than the effects of 10 mg/kg.
Effects of sertindole on ketamine-induced deficits
in the ASST
Similar to the two earlier experiments, 10 mg/kg of ketamine
administered 50 min before the sessions increased both the
number of trials (F(3, 84)=2.62, P<0.05; Fig. 3a) and errors
(F(3, 84)=2.67, P<0.05; Fig. 3c) to criterion during the EDS
phase. Sertindole + ketamine treatment decreased these
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Fig. 2 a–c Dose-dependent
effects of ketamine on the
attentional set-shifting task in
mice. Ketamine (10 or 20 mg/
kg) was administered 50 min
before both sessions. N=8–9
mice per treatment. Data are
presented as the mean ± SEM.
Symbols: *P<0.05 vs. vehicle,
iP<0.05 vs. IDS2 phase,
kP<0.05 vs. ketamine 10 mg/kg
group; Newman–Keuls post hoc
test
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significantly lower compared to the ketamine alone treat-
ment. Sertindole (2.5 mg/kg) did not change the number of
trials or errors to criterion during the EDS phase compared
with the vehicle-treated and sertindole + ketamine-treated
groups (Fig. 3a, c). In this set of data, the time to criterion
measure (Fig. 3b) was not affected by any of the treatments.
Dose-related effects of Ro 25-6981 on ASST performance
Ro 25-6981, administered 30 min before both sessions at
10 mg/kg, but not at 3 mg/kg, significantly and specifically
facilitated performance during the EDS phase. The higher
dose decreased the number of trials (F(6, 63)=4.97, P<0.001;
Fig. 4a) and errors (F(6, 63)=4.27, P<0.01; Fig. 4c) to
criterion compared to the vehicle-treated group and compared
to the group treated with the lower dose. The time to criterion
measure (Fig. 4b) was not affected by these treatments.
Effects of Ro 25-6981 on ketamine-induced deficits
in the ASST
Ketamine (10 mg/kg) increased the number of trials to
criterion during the EDS phase, but the Ro 25-6981
treatment alone (10 mg/kg) decreased this measure com-
pared to the vehicle-treated group (F(3, 84)=8.72, P<
0.001; Fig. 5a), confirming our earlier findings. The
administration of Ro 25-6981 to ketamine-pretreated mice
decreased the number of trials to criterion during the EDS
phase compared to the vehicle- and ketamine-treated groups
(Fig. 5a). A similar pattern of effects was observed for the
errors to criterion measure; however, this statistical analysis
yielded insignificant results (P=0.10; Fig. 5c). Ketamine
(10 mg/kg) prolonged the time to criterion during the EDS
phase (see also Fig. 2), and the ketamine + Ro 25-6981
treatment decreased this measure compared to the ketamine
alone group (F(3, 84)=4.09, P<0.01; Fig. 5b). Similar to
the earlier experiment, the Ro 25-6981 treatment shortened
the time to criterion compared to the vehicle-treated group,
but statistical analysis yielded insignificant differences.
Discussion
The present study demonstrated a procedure of attentional
set-shifting in mice capable of revealing a deficit during the
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Fig. 3 Effects of sertindole on
ketamine-induced deficits in the
attentional set-shifting task in
mice. Sertindole (2.5 mg/kg)
and ketamine (10 mg/kg) were
administered 2 h and 50 min
before both sessions, respec-
tively (N=7–9 mice per treat-
ment). Data are presented as the
mean ± SEM. Symbols: *
P<0.05 vs. vehicle, iP<0.05 vs.
IDS2 phase, kP<0.05 vs. ket-
amine 10 mg/kg group; New-
man–Keuls post hoc test
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administration. We confirmed that the atypical antipsychotic
sertindole alleviated ketamine-induced cognitive deficits. In
addition, the present data suggest that the NR2B subunit-
selective NMDA antagonist Ro 25-6981 not only facilitated
ASST performance during the EDS phase but also reversed
ketamine-induced cognitive inflexibility.
Only two published modifications of the primary ASST
procedure for rats (Birrell and Brown 2000) have success-
fully demonstrated significant EDS phase impairment in
mice (Garner et al. 2006; Papaleo et al. 2008). Because
mice were unable to complete the test in 1 day under our
experimental conditions, we divided the procedure into two
sessions and included additional phases (IDS2 and IDSR2).
As pointed out by Garner et al. (2006), like reversal phases
(CDR and IDSR), these additional phases serve to
strengthen the cognitive set formation. This outcome was
manifested by a general improvement in performance
during the phases ranging from CD to IDSR2 followed by
a poorer EDS phase performance, which is regarded as the
primary measure of set-shifting. Under these conditions, we
demonstrated reliable set-shifting in mice because, in all
replications (Figs. 1, 2, 3, 4, and 5), the subjects required
significantly more trials to reach the criterion during the
EDS phase than during the IDS2 phase of the task. A
drawback of the 2-day protocol is that the investigated
compound has to be administered twice, but the relatively
short duration of the test session could be considered as a
potential advantage for the investigation of compounds
characterized by a short half-life.
The present work confirms the results of Nikiforuk et al.
(2010) demonstrating that, in the rat ASST, ketamine
produces specific deficits in cognitive flexibility after a
single dose given 50 min before the test and extends these
findings to the mouse species. Although these studies
cannot be compared directly, the observed effect was dose
dependent; the higher dose of ketamine (20 mg/kg) more
severely impaired the task performance compared to the
lower dose (10 mg/kg). It was also time dependent; the ED
shift deficit was demonstrated at 50 min, but not 3 or 24 h,
following drug administration. The latter observation
somewhat contrasts with the findings of Egerton et al.
(2005), demonstrating that a single dose of PCP tested 24 h
after administration produced an ED shift impairment.
However, different NMDA receptor antagonists were used,
and the studies were performed in a different species.
Notably, in clinical experiments, WCST impairment is
observed 40 min after ketamine infusion (Krystal et al.
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Fig. 4 a–c Effects of Ro 25-
6981 on attentional set-shifting
task performance in mice. Ro
25-6981 (3 or 10 mg/kg) was
administered 30 min before both
sessions (N=8 mice per treat-
ment). Data are presented as the
mean ± SEM. Symbols:
*P<0.05 vs. vehicle, iP<0.05
vs. IDS2 phase, #P<0.05 vs. Ro
25-6981 at 3 mg/kg; Newman–
Keuls post hoc test
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measured by the Brief Psychiatric Rating Scale, disappeared
within 2 h after infusion (Berman et al. 2000; Zarate et al.
2006). Therefore, the current protocol appears to be a
promising pharmacological tool for modeling mouse cogni-
tive inflexibility. Its predictive validity is based on the
inhibitory effects of sertindole (Fig. 3), which also reduced
the impairing effects of PCP-like compounds in the rat ASST
in former studies (Rodefer et al. 2008; Broberg et al. 2009;
Goetghebeur and Dias 2009; Nikiforuk et al. 2010) and
alleviated the cognitive impairments associated with schizo-
phrenia (Gallhofer et al. 2007) and ketamine administration
in healthy volunteers (Vollenweider et al. 1999).
The major finding of this set of experiments concerns the
pro-cognitive effects of the NMDA NR2B subunit-selective
antagonist Ro 25-6981 in the mouse ASST. These effects
were shown by the reversal of the ketamine-induced
cognitive deficit (Fig. 5) and by cognitive improvement in
mice treated with Ro 25-6981 only (Fig. 4). The pro-cognitive
effects of the NR2B-selective antagonist are in sharp contrast
to the PCP-like antagonists, and to our knowledge, this is the
first demonstration of an NMDA antagonist-induced pro-
cognitive action in the ASST. The effects of NR2B-selective
antagonists on cognitive functions are complicated. The Ro
63-1908 does not affect performance in the Morris water
maze and delayed matching to position task (DMTP)
performance, though in 5-CSRT Ro 63-1908 produces an
increase in premature responses, and in differential rein-
forcement of low-rate 24 s (DRL24) task, it reduces the inter-
response time, suggesting an impairment of response
inhibition (Higgins et al. 2003). Although traxoprodil does
not affect spatial learning (Guscott et al. 2003), Ro 25-6981
disrupts spatial reversal learning and enhances perseveration
in the Morris water maze (Duffy et al. 2008). Consistent with
the latter report, NMDA 2B subunit over-expression results
in better performance in learning and memory tasks, like
novel object recognition, the Morris water maze, and the
t-maze, in mice (Tang et al. 1999; Cao et al. 2007) and rats
(Wang et al. 2009).
Nonetheless, in tasks specifically assessing cognitive
flexibility, like the 5-CSRT, both traxoprodil and Ro 25-
6981 (3–30 mg/kg) increase premature responding and
response speed with no error trade-off similar to Ro 63-
1908. At a short inter-trial interval, Ro 63-1908 reliably
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Fig. 5 a–c Effects of Ro 25-
6981 on ketamine-induced defi-
cits in the attentional set-shifting
task in mice. Ro 25-6981
(10 mg/kg) and ketamine
(10 mg/kg) were administered
30 and 50 min before both
sessions, respectively (N=8 mice
per treatment). Data are pre-
sented as the mean ± SEM.
Symbols: *P<0.05 vs. vehicle,
iP<0.05 vs. IDS2 phase,
kP<0.05 vs. ketamine 10 mg/kg
group; Newman–Keuls post hoc
test
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accuracy, and traxoprodil improves accuracy and increases
response speed in the DMTP task (Higgins et al. 2005).
These authors conclude that selective NR2B NMDA
antagonists promote impulsive-type responding that—under
certain test conditions, such as a higher event rate of
stimulus presentation—results in an improvement of task
performance. Somewhat similar results have been reported
by Gilmour et al. (2009), who show that NR2B-specific
antagonists increase instrumental output in a series of
variable interval schedules of reinforcement in an operant
task. Our data appear to confirm these findings because the
treatment with Ro 25-6981 not only reduced the number of
trials to criterion (Fig. 4a) but also reduced, albeit
insignificantly, the time required to complete the EDS
phase of the set-shifting task (Figs. 4b and 5b).
The present data cannot offer a convincing explanation
of the mechanism for the pro-cognitive action of Ro 25-
6981. The ASST does not allow for the measurement of all
of the parameters that are typically recorded in 5-CSRT and
is a relatively simple procedure with a remarkably lower
workload. Nonetheless, we may speculate that the Ro 25-
6981-induced reduction in the number of trials to criterion
and in the time to complete the EDS phase resembles a
similar improvement in performance (response speed and
accuracy) as the improvements found in the 5-CSRT
(Higgins et al. 2005). The ketamine-induced inhibition of
hippocampal NMDA receptors may enhance the firing rate
of glutamatergic PFC neurons and impair PFC-dependent
functions, including cognitive flexibility (Greene 2001;
Homayoun and Moghaddam 2007; Lisman et al. 2008). A
high density of the NR2B subunit within the PFC,
including infra-limbic regions (Wenzel et al. 1995),
confirmed by autoradiography with [3H]-Ro 25-6981
(Mutel et al. 1998), suggests that the compound exerted
its actions in the PFC. It is likely that the unique
localization of the NR2B-containing NMDA receptors
allows for the reversal of the ketamine-induced cognitive
deficit in ASST via blockade of glutamatergic cortical
disinhibition. Future studies will reveal the precise mech-
anism of the pro-cognitive action of this NR2B-selective
NMDA antagonist.
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